Committee advances amendment clarifying when cannabis products require additional testing; amendment passes 11–0

The joint standing committee on veterans and legal affairs advanced a sponsor amendment to LD1488, an act addressing cannabis testing and the manufacture of cannabis and hemp products, after a work session and roll‑call vote.

Miss Olsson, staff assisting the committee, told members the committee amendment previously reported had struck the original bill and inserted a narrower change to subsection 4 of Title 28‑B §605. She said that an earlier committee amendment carried a fiscal note to fund additional quality‑control testing and several positions; the amendment as reported to the Senate included appropriations she summarized for committee members. The sponsor’s current language returns to an original form and clarifies when additional testing is not required.

Sponsor Senator Tipping told the committee the amendment aligns with what the legislature previously approved and that it aims to remove language that generated a large fiscal note. He explained the clarification is intended so products already tested (for example, concentrates used to make edibles) are not subject to duplicate testing unless further processing would increase concentrations of contaminants or other factors identified in statute. He said the change is intended to avoid unnecessary testing burdens on small retailers and manufacturers.

Representative Ber moved that the committee report the bill as "ought to pass" on the sponsor’s yellow amendment; Representative Chapman seconded. The clerk called the role and the committee recorded 11 yeas, none opposed, and two members absent. The motion prevailed. The chair noted absent members have until Friday at noon to cast absentia votes and reminded members of vote‑sheet procedures.

Committee members asked for a later policy review of so‑called "final form" testing after staff distribute a ProPublica article referenced during the session that raised concerns about how intoxicating hemp products have shown up in other states’ cannabis products after testing. The chair said the committee will not take a large policy vote on those materials today but will schedule further discussion and a language review later.

The committee’s action advances the sponsor’s clarification to the next stage of the legislative process; the amendment replaces prior Senate amendments and removes an appropriations section that had produced a fiscal note attached to an earlier committee version.

Next step: committee staff will distribute the ProPublica reporting and related materials; the committee indicated it will revisit final‑form testing language and any necessary technical refinements in a subsequent language review.